JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

Phase 2

Active, not recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: Erdafitinib

First Posted Date: 2019-09-10

Last Posted Date: 2024-08-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 316

Registration Number: NCT04083976

Locations: 🇧🇪
Grand Hopital de Charleroi, site Notre Dame, Charleroi, Belgium
🇧🇪
CHU UCL Namur - Site Dinant, Dinant, Belgium
🇧🇪
UZA, Edegem, Belgium

and more 168 locations

A Study of JNJ-61393215 in the Treatment of Depression

Phase 2

Completed

Conditions: Major Depressive Disorder With Anxious Distress

Interventions: Drug: JNJ-61393215
Drug: Placebo

First Posted Date: 2019-09-06

Last Posted Date: 2023-07-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 222

Registration Number: NCT04080752

Locations: 🇺🇸
Collaborative NeuroScience Network, Garden Grove, California, United States
🇺🇸
Atlanta Institute, Alpharetta, Georgia, United States
🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States

and more 30 locations

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Lazertinib
Drug: Amivantamab
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2019-09-04

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 701

Registration Number: NCT04077463

Locations: 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸
UCSF Helen Diller Comprehensive, San Francisco, California, United States

and more 75 locations

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Lazertinib

First Posted Date: 2019-08-30

Last Posted Date: 2024-02-28

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 29

Registration Number: NCT04075396

Locations: 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Advent Health Orlando, Orlando, Florida, United States

and more 6 locations

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Phase 2

Completed

Conditions: Respiratory Syncytial Viruses

Interventions: Other: RSV Mobile Application
Drug: Placebo
Drug: JNJ-53718678 2.5 mg/kg
Drug: JNJ-53718678 3 mg/kg
Drug: JNJ-53718678 4.5 mg/kg

First Posted Date: 2019-08-28

Last Posted Date: 2022-06-08

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 22

Registration Number: NCT04068792

Locations: 🇨🇳
Chang Gung Memorial Hospital- Linkou, Taoyuan, Taiwan
🇵🇦
Cevaxin Avenida Mexico, Panama, Panama
🇧🇪
UZ Antwerpen, Edegem, Belgium

and more 7 locations

A Study of Paliperidone Palmitate 6-Month Formulation

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: PP6M injection Dose 1
Drug: PP6M injection Dose 2

First Posted Date: 2019-08-28

Last Posted Date: 2023-05-31

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 178

Registration Number: NCT04072575

Locations: 🇵🇱
Zespol Opieki Zdrowotnej w Chelmnie, Chelmno, Poland
🇦🇷
C.I.A.P. (Centro de investigación y Asistencia en Psiquiatría), Rosario, Argentina
🇦🇷
INSA Instituto de Neurociencias San Agustín, La Plata, Argentina

and more 27 locations

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Phase 3

Withdrawn

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Ustekinumab (approximately 6 mg/kg)
Drug: Placebo
Drug: Ustekinumab 90 milligram (mg)

First Posted Date: 2019-08-19

Last Posted Date: 2020-10-23

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT04060888

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China
🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
🇨🇳
Anhui Province Hospital, Hefei, China

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Phase 4

Completed

Conditions: Waldenstrom Macroglobulinemia

Interventions: Drug: Ibrutinib

First Posted Date: 2019-08-01

Last Posted Date: 2024-12-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 17

Registration Number: NCT04042376

Locations: 🇨🇳
Wuhan Union Hospital, Wuhan, China
🇨🇳
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, China

and more 3 locations

A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: JNJ-64140284

First Posted Date: 2019-07-26

Last Posted Date: 2020-01-13

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1

Registration Number: NCT04033458

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

Phase 2

Active, not recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Guselkumab

First Posted Date: 2019-07-26

Last Posted Date: 2024-12-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1064

Registration Number: NCT04033445

Locations: 🇨🇳
The Third Xiangya Hospital of Central Sourth University, Changsha, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, China
🇨🇳
Daping Hospital, Chongqing, China

and more 381 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy